Friday, June 4, 2021
Zoom Webinar Event
Creighton University, Omaha, Nebraska
Due to the COVID 19-pandemic, the 2020 & 2021 events were combined for a two-day, virtual event on June 3rd and 4th, 2021.
Creighton University, Omaha, Nebraska
Due to the COVID 19-pandemic, the 2020 & 2021 events were combined for a two-day, virtual event on June 3rd and 4th, 2021.
Speaker Information
Keynote Address
Lisa Cunningham, PhD
National Institute on Deafness and Other Communication Disorders
2021 Bellucci Prize Winner
"Atorvastatin reduces cisplatin-induced hearing loss"
National Institute on Deafness and Other Communication Disorders
2021 Bellucci Prize Winner
"Atorvastatin reduces cisplatin-induced hearing loss"
About Lisa Cunningham, PhD
Lisa Cunningham is a Senior Investigator and Chief of the Laboratory of Hearing Biology and Therapeutics at the National Institute on Deafness and Other Communication Disorders (NIDCD), one of the 27 institutes that comprise the US National Institutes of Health (NIH). Dr. Cunningham was trained clinically as an audiologist before obtaining a PhD in Neuroscience from the University of Virginia. She did a post-doctoral fellowship in auditory neuroscience at the University of Washington in Seattle. Dr. Cunningham’s lab conducts basic, translational, and clinical studies on sensory hair cell degeneration and hearing loss in the mature inner ear and develops therapeutic strategies to safeguard hearing.
Her basic science studies examine the cellular and molecular mechanisms that underlie sensory hair cell death and survival, and her translational studies use this mechanistic knowledge to guide the rational design of therapies aimed at preventing hearing loss in humans. Clinical studies in her lab test the efficacy of these potential therapeutic strategies. Of particular interest is the development of treatments aimed at protecting the hearing of patients receiving therapeutic drugs that cause hearing loss, so-called “ototoxic” drugs, which include some antibiotics and some anti-cancer drugs
Her basic science studies examine the cellular and molecular mechanisms that underlie sensory hair cell death and survival, and her translational studies use this mechanistic knowledge to guide the rational design of therapies aimed at preventing hearing loss in humans. Clinical studies in her lab test the efficacy of these potential therapeutic strategies. Of particular interest is the development of treatments aimed at protecting the hearing of patients receiving therapeutic drugs that cause hearing loss, so-called “ototoxic” drugs, which include some antibiotics and some anti-cancer drugs
2021 Trainee Award
Morning Podium Presentations
Jonathan Gale, PhD
University College London, U.K. "Discovering new molecular mechanisms for cochlear cell survival" |
Richard Salvi, PhD
State University of New York at Buffalo "Prevention of Noise, Drug and Age-Related Hearing Loss with Multifunctional and Other Antioxidants" |
Robert Frisina, Jr, PhD
University of South Florida "Recent Advances in BME and Neuroengineering Approaches to Treating Hearing Loss" |
Afternoon Corporate/Academic Speakers
Jonas Dyhrfjeld-Johnsen, PhD
Chief Development Officer Acousia Therapeutics "Small molecule drugs for hearing loss - the current development perspective of Acousia" Marisa Zallocchi, PhD
Chief Scientific Officer Ting Therapeutics LLC "Preclinical Studies of Novel Otoprotectants Against Cisplatin-and Noise-Induced Hearing Loss" |
Hubert Löwenheim, MD, PhD
University of Tubingen "Otoprotection form cisplatin induced hearing loss by a potassium channel agonist" Michelle D. Valero, PhD
Senior Director, Head of Anatomy and Physiology Akouos, Inc "Durable Recovery of Auditory Function Following Intracochlear Delivery of AK-OTOF (AAVAnc80-hOTOF Vector) in a Translationally Relevant Mouse Model of Otoferlin Gene (OTOF)-mediated Hearing Loss" |
Debashree Mukherjea, PhD
Founder and CEO
Novear Therapeutics LLC
"Drug repurposing for hearing restoration"
Founder and CEO
Novear Therapeutics LLC
"Drug repurposing for hearing restoration"
Sponsored by the Bellucci DePaoli Family Foundation. Alumnus Dr. Richard J. Bellucci, MD '42 was a national leader in the utilization of ear surgical techniques to treat conductive hearing loss. Questions? Email [email protected]. |
Hybrid One-Day Event
May 17, 2024 Free Attendance |